SHARED：一项旨在破解丙型肝炎耐药性的国际合作。

SHARED: An International Collaboration to Unravel Hepatitis C Resistance.

机构信息

British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

出版信息

Viruses. 2021 Aug 10;13(8):1580. doi: 10.3390/v13081580.

DOI:10.3390/v13081580

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8402898/

Abstract

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...].

摘要

直接作用抗病毒药物（DAAs）的出现改变了丙型肝炎的治疗格局[... ]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7a/8402898/678c7b5db714/viruses-13-01580-g001.jpg

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

SHARED: An International Collaboration to Unravel Hepatitis C Resistance.

Viruses. 2021 Aug 10;13(8):1580. doi: 10.3390/v13081580.

2

Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.

Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1.

3

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].

Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):170-174. doi: 10.3760/cma.j.issn.1007-3418.2017.03.003.

4

[Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].

Nihon Rinsho. 2015 Dec;73 Suppl 9:189-92.

5

[A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].

Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):165-9. doi: 10.3760/cma.j.issn.1007-3418.2016.03.002.

6

Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.

Drug Discov Today Technol. 2014 Mar;11:19-25. doi: 10.1016/j.ddtec.2013.12.003.

7

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.

World J Gastroenterol. 2017 Dec 14;23(46):8120-8127. doi: 10.3748/wjg.v23.i46.8120.

8

Clinical relevance of HCV antiviral drug resistance.

Curr Opin Virol. 2012 Oct;2(5):651-5. doi: 10.1016/j.coviro.2012.08.008. Epub 2012 Sep 21.

9

Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals.

Am J Trop Med Hyg. 2020 Nov;103(5):2083-2084. doi: 10.4269/ajtmh.20-0367.

10

Hepatitis C Virus: Viral Quasispecies and Genotypes.

Int J Mol Sci. 2017 Dec 22;19(1):23. doi: 10.3390/ijms19010023.

引用本文的文献

1

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.

Clin Infect Dis. 2024 Dec 17;79(6):1437-1446. doi: 10.1093/cid/ciae431.

2

Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.

JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul.

3

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.

Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035.

4

Hepatitis C: recent advances and practical management.

Frontline Gastroenterol. 2023 Jun 13;14(5):415-421. doi: 10.1136/flgastro-2022-102373. eCollection 2023.

5

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.

Front Pharmacol. 2022 Apr 27;13:894460. doi: 10.3389/fphar.2022.894460. eCollection 2022.

6

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.

JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May.

7

Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay.

Viruses. 2021 Aug 30;13(9):1721. doi: 10.3390/v13091721.

本文引用的文献

1

Treatment failure with DAA therapy: Importance of resistance.

J Hepatol. 2021 Jun;74(6):1472-1482. doi: 10.1016/j.jhep.2021.03.004. Epub 2021 Mar 12.

2

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study.

Open Forum Infect Dis. 2021 Jan 6;8(2):ofab006. doi: 10.1093/ofid/ofab006. eCollection 2021 Feb.

3

Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.

J Hepatol. 2020 Oct;73(4):794-799. doi: 10.1016/j.jhep.2020.05.029. Epub 2020 May 26.

4

Transmission of NS5A-Inhibitor Resistance-Associated Substitutions Among Men Who Have Sex With Men Recently Infected with Hepatitis C Virus Genotype 1a.

Clin Infect Dis. 2020 Nov 5;71(8):e215-e217. doi: 10.1093/cid/ciaa145.

5

DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?

J Hepatol. 2019 Dec;71(6):1070-1072. doi: 10.1016/j.jhep.2019.09.021. Epub 2019 Oct 21.

6

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.

J Hepatol. 2019 Dec;71(6):1099-1105. doi: 10.1016/j.jhep.2019.07.025. Epub 2019 Aug 7.

7

Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1. Epub 2018 Dec 14.

8

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. doi: 10.1016/S2468-1253(18)30382-0. Epub 2018 Dec 11.

9

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C.

J Virus Erad. 2018 Jul 1;4(3):179-181. doi: 10.1016/S2055-6640(20)30267-3.

10

Nextstrain: real-time tracking of pathogen evolution.

Bioinformatics. 2018 Dec 1;34(23):4121-4123. doi: 10.1093/bioinformatics/bty407.